Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022
The DOI matches its Crossref record; 18 of the 20 references it cites were found in a registry or an index.
Abstract
Rationale Withdrawal syndrome (WDS) has been described after discontinuation of antipsychotics. WDS could be the consequence of an over-activation of the dopaminergic pathway. Antipsychotics with a higher affinity for dopamine D2 receptors could be associated with a higher risk of WDS. This study aims to address this statement and evaluate the risk difference for withdrawal syndrome between antipsychotics based on pharmacovigilance data. Methods We collected individual reports registered in Vigibase® between 01/01/2000 and 31/12/2022 of patients treated with antipsychotics and who had presented WDS. A disproportionality analysis was performed to evaluate the risk of reporting WDS with each antipsychotic compared to all other antipsychotics. We performed a correlation analysis to assess the correlation between the risk of reporting WDS for each antipsychotic in relation with their pKi for D2 and 5HT2A receptors. Results The most frequent psychiatric withdrawal symptoms after antipsychotic discontinuation were insomnia, anxiety and depression. Tremor, headache and dizziness were among the most frequently reported neurologic withdrawal symptoms. Tiotixene had the highest risk of reporting WDS (ROR 7.08; 95%CI 3.49 - 14.35) followed by pimozide (ROR 4.35; 95%CI 1.93 - 9.77), quetiapine (ROR 4.24; 95%CI 3.87 - 4.64), thioridazine (ROR 4.17; 95%CI 2.50-6.98) and ziprasidone (ROR 2.98; 95%CI 2.41-3.67). We found a poor correlation between D2/5HT2A binding affinity and the risk of re…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Case-non-case studies: principle, methods, bias and interpretation
Faillie, J.-L. (2019) · Therapies · doi:10.1016/j.therap.2019.01.006 · Cited by 336
Watson, S., Caster, O., Rochon, P. A., & den Ruijter, H. (2019) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.10.001 · Cited by 302
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270 · cited 1×
“Indeed, long term treatment with antipsychotics could lead to an increased dopaminergic response after discontinuation (Chouinard et al. 2017).”
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265 · cited 1×
“(Brandt et al. 2022, 2020; Cosci and Chouinard 2020) It could be argued that those receptors might undergo a similar upregulation process as seen in dopaminergic receptors resulting in receptor supersensitivity and subsequent withdrawal symptoms.”
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157 · cited 2×
“(Horowitz et al. 2021).”
Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967183 · Cited by 77 · cited 1×
“(Guy et al. 2020) Moreover, disproportionality analysis can only Fig.”
Antipsychotic Withdrawal Symptoms: A Systematic Review and Meta-Analysis
Brandt, L., Bschor, T., Henssler, J., Müller, M., Hasan, A., Heinz, A., & Gutwinski, S. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.569912 · Cited by 56
Kusumi, I., Takahashi, Y., Suzuki, K., et al. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050024 · Cited by 48
Serotonin Syndrome Associated With Clozapine Withdrawal
Stevenson, E., Schembri, F., Green, D. M., & Burns, J. D. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.95 · Cited by 39
Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis
Brandt, L., Schneider‐Thoma, J., Siafis, S., Efthimiou, O., Bermpohl, F., Loncar, L., Neumann, K., Hasan, A., Heinz, A., Leucht, S., et al. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00014-1 · Cited by 35
Cited by
Gangadin, S. S., de Beer, F., Wijnen, B. F. M., Begemann, M., van Beveren, N. J. M., Boonstra, N., de Haan, L., Kikkert, M., Koops, S., van Os, J., et al. (2025) · World Psychiatry · doi:10.1002/wps.21315 · Cited by 28
“A re cent pharmacovigilance study explored the relationship between neurotransmitter receptor affinities and the risk of reporting with drawal symptoms, but did not find a significant association 52 .”
Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety
Cuevas, C. D. L., Sanz, E. J., & de León, J. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s495254 · Cited by 32
“In the context of study of all kinds of antipsychotic-induced withdrawal syndromes, Storck et al 72 reported that clozapine had a lower risk.”
He, L., Shen, M., Zhang, L., Li, Y., & Li, H. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00869-4 · Cited by 5
“Withdrawal syndrome from OLZ may include symptoms such as psychiatric manifestations, neurological symptoms, cholinergic rebound, and movement disorders [20, 21].”
Jing, H., Jie, D., Zhong, W., et al. (2026) · Frontiers in Health Services · doi:10.3389/frhs.2025.1741402 · Cited by 3
Use of Atypical Antipsychotics in Pediatric Populations
Heuer, B., & Whited, T. (2026) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2025.12.020
Strawn, J. R., & Stahl, S. M. (2026) · doi:10.1017/9781009642187.013
Reducing Restraint Use in the Pediatric Agitated Patient
Green, D. L., & Uspal, N. G. (2026) · Advances in Pediatrics · doi:10.1016/j.yapd.2026.02.001
Huang, W., Shen, J., & Zhang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1856410
“VigiBase’s absence of data regarding dosing regimens, clinical indications, mortality timing, and other crucial parameters precludes comprehensive competing risk analyses (Storck et al., 2024).”
Recommendations on switching or deprescribing hypnotic medications for insomnia
Hajak, G., Fietze, I., Schöbel, C., Saletu, M., Högl, B., & Winter, Y. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2026.0141
Khan, Z., Doherty, A. S., McCarthy, C., Dalton, K., Jungo, K. T., Reeve, E., & Moriarty, F. (2026) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2026.100828 · Cited by 2
“28,29 The limited studies evaluating ADWE reports in pharmacovigilance data have generally focused on a single drug., 30 – 32 or specific drug classes, 5,33,34 resulting in fragmented evidence and highlighting the need for further investigation to provide a comprehensive assessment of ADWEs.”
Metadata
- Authors
- Storck, W., de Laportalière, T. T., Yrondi, A., Javelot, H., Berna, F., & Montastruc, F.
- Affiliations
- Centre Hospitalier Universitaire de Toulouse (FR)
- Université de Strasbourg (FR)
- Inserm (FR)
- Corresponding author
- Storck, Wilhelm
- Venue
- Psychopharmacology
- Published
- 2024-02-20
- Volume
- 241
- Issue
- 6
- Pages
- 1205-1212
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W4391981454
- Cited by
- 10
- References
- 20
- Citations by year
- 2026: 7 · 2025: 2 · 2024: 1
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- antipsychotic discontinuation, pimozide, quetiapine, thioridazine, ziprasidone, withdrawal symptoms, pharmacovigilance, disproportionality analysis, adverse drug reactions, antipsychotic drugs, rebound
- MeSH terms
- Adult, Aged, Female, Humans, Male, Middle Aged, Substance Withdrawal Syndrome, Antipsychotic Agents, Databases, Factual, Adverse Drug Reaction Reporting Systems, Receptors, Dopamine D2, Young Adult, Pharmacovigilance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.